CENTRE DE BIOTECHNOLOGIE DE SFAX - CBS

Their core work

CBS is a Tunisian public research centre based in Sfax with expertise split across two areas of applied biotechnology: plant-derived natural products (phytochemistry, essential oils, by-product valorisation) and microbial biocontrol agents — specifically Bacillus thuringiensis-based biopesticides. In EU projects they have contributed hands-on scientific work ranging from phytochemical extraction and cosmeceutical development to biopesticide bioprocess intensification, scale-up, and formulation for agricultural field use. Their most recent H2020 engagement (IPM-4-Citrus) explicitly targeted the path from lab to market, including economic maturation and spin-off creation, suggesting they can move beyond pure research toward commercialisation support. As a non-EU participant in MSCA-RISE consortia, they also provide European partners with access to North African research infrastructure and field-testing contexts relevant to Mediterranean agriculture.

What they specialise in

How they've shifted over time

CBS entered H2020 (2016) through plant-based natural products — phytochemistry, essential oil by-products, and their application in cosmeceuticals and food supplements, characteristic of a centre with classical biochemistry and extraction capabilities. By 2017 their second project pivoted sharply toward applied microbial biotechnology: Bacillus thuringiensis, d-endotoxin characterisation, and the full bioprocess pipeline from culture to formulated field product. The shift is not a contradiction but a broadening — both tracks share an eco-friendly, bio-based philosophy — and the more recent project adds a clear commercial dimension (spin-off, economic maturation) absent from the earlier work.

CBS is moving from upstream natural product research toward applied microbial biocontrol with explicit commercialisation goals, making them an increasingly relevant partner for consortia targeting agri-biotech market entry rather than pure discovery.

How they like to work

CBS has never held a coordinator role in H2020 — both participations are as partner or participant within large MSCA-RISE consortia. MSCA-RISE projects are inherently expansive mobility networks, which explains how an organisation with just 2 projects accumulates 21 unique partners across 11 countries. This profile suggests CBS is a reliable specialist contributor that integrates smoothly into large international teams rather than an organisation that drives project strategy. For a prospective partner, this means CBS brings well-defined scientific tasks and field access in Tunisia without requiring consortium management support in return.

Twenty-one unique consortium partners spread across 11 countries from just two projects is a notably wide network for an organisation of this scale, a direct consequence of MSCA-RISE's staff-exchange model which links many institutions simultaneously. The network almost certainly spans both EU member states and associated/third countries, consistent with CBS's own status as a non-EU MSCA-RISE partner from Tunisia.

What sets them apart

CBS is one of the very few Tunisian research centres with direct H2020 project participation, giving European consortia a credentialed, EU-vetted partner for North African field trials and local agricultural knowledge — particularly valuable for Mediterranean crop research such as citrus IPM. Their dual capability in both plant phytochemistry and microbial biopesticides is uncommon: most biocontrol groups focus on one or the other, whereas CBS can contribute across the full bio-based crop protection pipeline. For companies or consortia targeting eco-certified biopesticide products or plant-derived functional ingredients, CBS offers research depth combined with proximity to North African production regions and lower collaboration costs than equivalent EU institutes.

Highlights from their portfolio

• IPM-4-Citrus
  The most substantive CBS engagement — a six-year MSCA-RISE project explicitly structured to move Bacillus thuringiensis biopesticides from laboratory to commercial product, with CBS receiving EUR 144,000 in direct EC funding and contributing across bioprocess, formulation, field testing, and spin-off development stages.
• EXANDAS
  Demonstrates CBS's earlier phytochemistry capability, focusing on valorising aromatic plant by-products for cosmeceutical and food supplement markets — a different application domain that reveals the breadth of the centre's natural products expertise.